During the last session, Oruka Therapeutics Inc (NASDAQ:ORKA)’s traded shares were 0.15 million, with the beta value of the company hitting 0.34. At the end of the trading day, the stock’s price was $9.22, reflecting an intraday gain of 7.08% or $0.61. The 52-week high for the ORKA share is $33.00, that puts it down -257.92 from that peak though still a striking 40.46% gain since the share price plummeted to a 52-week low of $5.49. The company’s market capitalization is $345.20M, and the average intraday trading volume over the past 10 days was 0.46 million shares, and the average trade volume was 300.73K shares over the past three months.
Oruka Therapeutics Inc (NASDAQ:ORKA) trade information
Oruka Therapeutics Inc (ORKA) registered a 7.08% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.08% in intraday trading to $9.22, hitting a weekly high. The stock’s 5-day price performance is 25.10%, and it has moved by -20.72% in 30 days. Based on these gigs, the overall price performance for the year is -56.31%. The short interest in Oruka Therapeutics Inc (NASDAQ:ORKA) is 1.52 million shares and it means that shorts have 7.03 day(s) to cover.
The consensus price target of analysts on Wall Street is $20, which implies an increase of 53.9% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20 and $20 respectively. As a result, ORKA is trading at a discount of -116.92% off the target high and -116.92% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 36.88%. While earnings are projected to return 39.53% in 2025, the next five years will return 16.79% per annum.
ORKA Dividends
Oruka Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Oruka Therapeutics Inc (NASDAQ:ORKA)’s Major holders
Oruka Therapeutics Inc insiders own 3.25% of total outstanding shares while institutional holders control 85.78%, with the float percentage being 88.66%.
